drugset / Trial / NCT07082842

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

NCT07082842

Phase 3 Recruiting 472 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)

Timeline

Start
2025-10-27
Primary completion
2031-01-15
Completion
2032-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC585 Small molecule
Comparator Pirfenidone Small molecule